ARWR - Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday? | Benzinga
On Monday, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) released topline results from the Phase 3 PALISADE study of plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS).
FCS is a rare metabolic disease that prevents the body from digesting fats.
The study met the primary endpoint of lowering triglycerides and all key secondary endpoints, including reducing the incidence of acute pancreatitis compared to ...